Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2006

Oncalis and ChemDiv Tackle Cancer-related Kinase Targets

  • Oncalis and ChemDiv entered into an R&D collaboration to discover candidates inhibiting receptor tyrosine kinase and other cancer-related targets. Oncalis will apply its yeast cell-based technology and develop biological assays, and ChemDiv will apply its medicinal chemistry and in vitro and in vivo biology services.

    ChemDiv provided the source for leads to the yeast-based screening platform that is now completely acquired by Oncalis, together with a high-throughput screening platform and IP rights on research projects.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »